Electroconvulsive therapy - Revision history

Chris.Rishel at 06:11, 22 February 2022

2022-02-22T06:11:26Z

← Older revision		Revision as of 23:11, 21 February 2022
Line 1:		Line 1:
	#
	{{Infobox surgical procedure		{{Infobox surgical procedure
	\| anesthesia_type = General		\| anesthesia_type = General
Line 8:		Line 7:
	\| considerations_intraoperative =		\| considerations_intraoperative =
	\| considerations_postoperative =		\| considerations_postoperative =
	}}Electroconvulsive therapy (ECT) is a medically induced generalized seizure that consists of a 2 to 3 second latent phase is followed by a tonic (prolonged muscular contraction) phase lasting 10 to 12 seconds, then a clonic (repeated contraction) phase of 30 to 50 seconds.<ref name=":0">{{Cite book\|last=Murray, Michael J, Steven H. Rose, Denise J. Wedel, C T. Wass, Barry A. Harrison, and Jeff T. Mueller.\|first=\|title=Faust's Anesthesiology Review\|publisher=\|year=2015\|isbn=\|location=Print\|pages=Anesthesia for Electroconvulsive Therapy; 490-492}}</ref><ref name=":1">{{Cite book\|last=Pardo, Manuel, Ronald D Miller\|first=\|title=Basics of Anesthesia 7th Edition\|publisher=\|year=2017\|isbn=0323401155\|location=Print\|pages=669-671}}</ref> It is used for refractory depression (unipolar and bipolar types), depression with psychotic features, schizophrenia, and catatonia.<ref name=":1" /><ref name=":2">{{Cite web\|last=ACCRAC\|date=2019-03-13\|title=Episode 112: Anesthesia for ECT with Christina Miller\|url=http://accrac.com/episode-112-anesthesia-for-ect-with-christina-miller/\|access-date=2021-08-22\|website=ACCRAC Podcast\|language=en}}</ref>		}}'''Electroconvulsive therapy''' (ECT) is a medically induced generalized seizure that consists of a 2 to 3 second latent phase is followed by a tonic (prolonged muscular contraction) phase lasting 10 to 12 seconds, then a clonic (repeated contraction) phase of 30 to 50 seconds.<ref name=":0">{{Cite book\|last=Murray, Michael J, Steven H. Rose, Denise J. Wedel, C T. Wass, Barry A. Harrison, and Jeff T. Mueller.\|first=\|title=Faust's Anesthesiology Review\|publisher=\|year=2015\|isbn=\|location=Print\|pages=Anesthesia for Electroconvulsive Therapy; 490-492}}</ref><ref name=":1">{{Cite book\|last=Pardo, Manuel, Ronald D Miller\|first=\|title=Basics of Anesthesia 7th Edition\|publisher=\|year=2017\|isbn=0323401155\|location=Print\|pages=669-671}}</ref> It is used for refractory depression (unipolar and bipolar types), depression with psychotic features, schizophrenia, and catatonia.<ref name=":1" /><ref name=":2">{{Cite web\|last=ACCRAC\|date=2019-03-13\|title=Episode 112: Anesthesia for ECT with Christina Miller\|url=http://accrac.com/episode-112-anesthesia-for-ect-with-christina-miller/\|access-date=2021-08-22\|website=ACCRAC Podcast\|language=en}}</ref>

	ECT is monitored by EEG, with electrodes placed in left unilateral, right unilateral (most common, fewer memory side effects), and bifrontal. Goal seizure duration is 30-60 seconds. For seizures lasting longer than 120 seconds, termination can be achieved with midazolam/propofol. The initial session may require a dose titration to determine the appropriate electrical stimulus to evoke a seizure. Both the duration of individual seizure & cumulative seizure time between treatments correlated w/ clinical improvement of depression, with total number of ECT sessions determined by patient's clinical response. Repeated rounds of ECT have been shown to increase seizure threshold (try to decrease dose of methohexital or other induction agent if possible to limit size of electrical charge administered).		ECT is monitored by EEG, with electrodes placed in left unilateral, right unilateral (most common, fewer memory side effects), and bifrontal. Goal seizure duration is 30-60 seconds. For seizures lasting longer than 120 seconds, termination can be achieved with midazolam/propofol. The initial session may require a dose titration to determine the appropriate electrical stimulus to evoke a seizure. Both the duration of individual seizure & cumulative seizure time between treatments correlated w/ clinical improvement of depression, with total number of ECT sessions determined by patient's clinical response. Repeated rounds of ECT have been shown to increase seizure threshold (try to decrease dose of methohexital or other induction agent if possible to limit size of electrical charge administered).
Line 25:		Line 24:
	* Severe osteoporosis (fracture risk)		* Severe osteoporosis (fracture risk)
	* Thrombophlebitis		* Thrombophlebitis


	Generally speaking, anesthetic considerations for the procedure are as follows:<ref name=":0" /><ref name=":1" />		Generally speaking, anesthetic considerations for the procedure are as follows:<ref name=":0" /><ref name=":1" />
Line 33:		Line 31:
	# Bite guard placed prior to ECT initiation		# Bite guard placed prior to ECT initiation
	# After ECT & seizure completed remove bite guard and provide supportive airway management until patient regains consciousness.		# After ECT & seizure completed remove bite guard and provide supportive airway management until patient regains consciousness.


	== Preoperative management ==		== Preoperative management ==
Line 43:		Line 40:
	!Considerations		!Considerations
	\|-		\|-
	\|Neurologic~~/Psychiatric~~		\|Airway
			\|
			\|-
			\|Neurologic
	\|Careful titration of psych meds (see below)		\|Careful titration of psych meds (see below)
	\|-		\|-

Chris.Rishel: Text replacement - "|Respiratory" to "|Pulmonary"

2022-02-22T05:45:20Z

Text replacement - "|Respiratory" to "|Pulmonary"

← Older revision		Revision as of 22:45, 21 February 2022
Line 49:		Line 49:
	\|Electrical activity can affect ICD/pacemaker (see below)		\|Electrical activity can affect ICD/pacemaker (see below)
	\|-		\|-
	\|~~Respiratory~~		\|Pulmonary
	\|		\|
	\|-		\|-

Tony.Wang: Clarifying information

2021-08-30T17:35:32Z

Clarifying information

← Older revision		Revision as of 10:35, 30 August 2021
Line 1:		Line 1:
	#		#
	{{Infobox surgical procedure		{{Infobox surgical procedure
	\| anesthesia_type =		\| anesthesia_type = General
	\| airway =		\| airway = Natural airway
	\| lines_access =		\| lines_access = 1 PIV
	\| monitors =		\| monitors = Standard ASA, EEG
	\| considerations_preoperative =		\| considerations_preoperative =
	\| considerations_intraoperative =		\| considerations_intraoperative =
Line 43:		Line 43:
	!Considerations		!Considerations
	\|-		\|-
	\|Neurologic		\|Neurologic/Psychiatric
	\|		\|Careful titration of psych meds (see below)
	\|-		\|-
	\|Cardiovascular		\|Cardiovascular
	\|		\|Electrical activity can affect ICD/pacemaker (see below)
	\|-		\|-
	\|Respiratory		\|Respiratory
Line 78:		Line 78:
	** MAO Inhibitors: Avoid ephedrine (indirect-acting sympathomimetics cause exaggerated BP). Be aware they ↓ plasma cholinesterase activity → ↑ succinylcholine duration		** MAO Inhibitors: Avoid ephedrine (indirect-acting sympathomimetics cause exaggerated BP). Be aware they ↓ plasma cholinesterase activity → ↑ succinylcholine duration
	** Lithium – Risk for delayed awakening, memory loss, and postictal confusion. Hold for 12hr before ECT		** Lithium – Risk for delayed awakening, memory loss, and postictal confusion. Hold for 12hr before ECT
	**''Benzodiazepines'' – Hold for 12hr before ECT. May need to give flumazenil before ECT to have an adequate seizure duration.		**Benzodiazepines – Hold for 12hr before ECT. May need to give flumazenil before ECT to have an adequate seizure duration.
	*''Pacemaker vs Implantable Cardioverter-Defibrillator (ICD)'':		*''Pacemaker vs Implantable Cardioverter-Defibrillator (ICD)'':
	** Pacemaker		** Pacemaker
	*** If ''~~Not~~'' dependent on the device, a magnet should be available in event of device failure.		*** If ''not'' dependent on the device, a magnet should be available in event of device failure.
	*** If ~~Dependent~~ on pacemaker, program device to asynchronous mode & a backup pacing mode should be available.		*** If dependent on pacemaker, program device to asynchronous mode & a backup pacing mode should be available.
	** ICD:		** ICD:
	*** Risk that the device misinterprets muscle movements as an abnormal cardiac rhythm and a discharge is possible.		*** Risk that the device misinterprets muscle movements as an abnormal cardiac rhythm and a discharge is possible.
	*** Device should be deactivated & an external defibrillator should be immediately available with placement of external defibrillator pads strongly considered.		*** Device should be deactivated & an external defibrillator should be immediately available with placement of external defibrillator pads strongly considered.
	** For a patient with an ICD & who is pacemaker dependent, the EP service should be consulted or in any other cases with pacing concerns.		** For a patient with an ICD & who is pacemaker dependent, the EP service should be consulted or in any other cases with pacing concerns.

	~~=== Regional and neuraxial techniques<!-- Describe any potential regional and/or neuraxial techniques which may be used for this case. If none, this section may be removed. --> ===~~

	== Intraoperative management ==		== Intraoperative management ==

	=== Monitoring and access<!-- List and/or describe monitors and access typically needed for this case. Please describe rationale for any special monitors or access. --> ===		=== Monitoring and access<!-- List and/or describe monitors and access typically needed for this case. Please describe rationale for any special monitors or access. --> ===
	~~PIV x 1~~

	Standard ASA monitors with 5 lead ECG. Single lead EEG		* PIV x 1
			* Standard ASA monitors with 5 lead ECG
			* Single lead EEG

	=== Induction and airway management<!-- Describe the important considerations and general approach to the induction of anesthesia and how the airway is typically managed for this case. --> ===		=== Induction and airway management<!-- Describe the important considerations and general approach to the induction of anesthesia and how the airway is typically managed for this case. --> ===
Line 140:		Line 139:

	=== Pain management<!-- Describe the expected level of postoperative pain and approaches to pain management for this case. --> ===		=== Pain management<!-- Describe the expected level of postoperative pain and approaches to pain management for this case. --> ===
			Minimal pain

	=== Potential complications<!-- List and/or describe any potential postoperative complications for this case. --> ===		=== Potential complications<!-- List and/or describe any potential postoperative complications for this case. --> ===
Line 145:		Line 145:
	* Post-ECT Delirium (or if flumazenil given pre-induction): treat with midazolam 1-2mg		* Post-ECT Delirium (or if flumazenil given pre-induction): treat with midazolam 1-2mg

	== Procedure variants<!-- This section should only be used for cases with multiple approaches (e.g. Laparoscopic vs. open appendectomy). Otherwise, remove this section. Use this table to very briefly compare and contrast various aspects between approaches. Add or remove rows as needed to maximize relevance. Consider using symbols rather than words when possible (e.g. +, –, additional symbols such as ↑ and ↓ are available using the "Ω" tool in the editor). --> ==

	~~{\| class="wikitable wikitable-horizontal-scroll"~~
	\|+
	!
	~~!Variant 1~~
	~~!Variant 2~~
	\|-
	~~\|Unique considerations~~
	\|
	\|
	\|-
	~~\|Position~~
	\|
	\|
	\|-
	~~\|Surgical time~~
	\|
	\|
	\|-
	~~\|EBL~~
	\|
	\|
	\|-
	~~\|Postoperative disposition~~
	\|
	\|
	\|-
	~~\|Pain management~~
	\|
	\|
	\|-
	~~\|Potential complications~~
	\|
	\|
	\|}
	== References ==		== References ==
	<references />		<references />

	[[Category:Surgical procedures]]		[[Category:Surgical procedures]]

Tony.Wang: Format changes

2021-08-30T17:30:38Z

Format changes

← Older revision		Revision as of 10:30, 30 August 2021
Line 14:		Line 14:
	Mortality risk is extremely low, at <1 in 75,000 treatments.<ref name=":0" /> Most common adverse events include transient arrhythmias (10%–40%), gastric aspiration (2.5%), and MSK disorders (0.4%) including fractures. Additional adverse events include pulmonary edema, headache, memory disturbance, and agitation. Very rarely Takotsubo cardiomyopathy, febrile reactions, or neurologic dysfunction may occur.		Mortality risk is extremely low, at <1 in 75,000 treatments.<ref name=":0" /> Most common adverse events include transient arrhythmias (10%–40%), gastric aspiration (2.5%), and MSK disorders (0.4%) including fractures. Additional adverse events include pulmonary edema, headache, memory disturbance, and agitation. Very rarely Takotsubo cardiomyopathy, febrile reactions, or neurologic dysfunction may occur.

	Absolute contraindications include		Absolute contraindications include:
	*<u>ABSOLUTE Contraindications</u>:<ref name=":0" /><ref name=":~~2" />~~		* Untreated Pheochromocytoma
	** Untreated Pheochromocytoma		* Intracranial mass/↑ ICP
	** Intracranial mass/↑ ICP		* Recent MI or Stroke w/in last 30 days
	** Recent MI or Stroke w/in last 30 days		Relative contraindications include:
	*<u>Relative ~~Contraindications</u>~~:~~<ref name=":0" />~~		* Angina pectoris, CHF
	** Angina pectoris, CHF		* COPD
	** COPD		* Glaucoma, Retinal detachment
	** Glaucoma, Retinal detachment		* High-risk pregnancy
	** High-risk pregnancy		* Severe osteoporosis (fracture risk)
	** Severe osteoporosis (fracture risk)		* Thrombophlebitis
	** Thrombophlebitis
	*<u>General Procedural Steps</u>: <ref name=":1" /><ref name=":2" />
	*# Pre-oxygenate well prior to induction		Generally speaking, anesthetic considerations for the procedure are as follows:<ref name=":0" /><ref name=":1" />
	*# Once induction medications given & patient unconscious start mask ventilating & give paralytic		# Pre-oxygenate well prior to induction
	*# Hyperventilate -> Hypocarbia (↓ seizure threshold)		# Once induction medications given & patient unconscious start mask ventilating & give paralytic
	*# Bite guard placed prior to ECT initiation		# Hyperventilate -> Hypocarbia (↓ seizure threshold)
	*# After ECT & seizure completed remove bite guard and provide supportive airway management until patient regains consciousness.		# Bite guard placed prior to ECT initiation
			# After ECT & seizure completed remove bite guard and provide supportive airway management until patient regains consciousness.


Line 113:		Line 114:
	*# Nitroglycerin &/or Beta blockers (esmolol, labetalol) can be used to attenuate sympathetic response.		*# Nitroglycerin &/or Beta blockers (esmolol, labetalol) can be used to attenuate sympathetic response.
	*#''Hyperglycemia'' often seen in insulin dependent Pt -> BG Pre/Post		*#''Hyperglycemia'' often seen in insulin dependent Pt -> BG Pre/Post
	*'''Post-ECT Delirium''' (or if flumazenil given pre-induction):
	*# Midazolam 1-2mg

	=== Positioning<!-- Describe any unique positioning considerations, including potential intraoperative position changes. If none, this section may be removed. --> ===		=== Positioning<!-- Describe any unique positioning considerations, including potential intraoperative position changes. If none, this section may be removed. --> ===
Line 143:		Line 142:

	=== Potential complications<!-- List and/or describe any potential postoperative complications for this case. --> ===		=== Potential complications<!-- List and/or describe any potential postoperative complications for this case. --> ===

			* Post-ECT Delirium (or if flumazenil given pre-induction): treat with midazolam 1-2mg

	== Procedure variants<!-- This section should only be used for cases with multiple approaches (e.g. Laparoscopic vs. open appendectomy). Otherwise, remove this section. Use this table to very briefly compare and contrast various aspects between approaches. Add or remove rows as needed to maximize relevance. Consider using symbols rather than words when possible (e.g. +, –, additional symbols such as ↑ and ↓ are available using the "Ω" tool in the editor). --> ==		== Procedure variants<!-- This section should only be used for cases with multiple approaches (e.g. Laparoscopic vs. open appendectomy). Otherwise, remove this section. Use this table to very briefly compare and contrast various aspects between approaches. Add or remove rows as needed to maximize relevance. Consider using symbols rather than words when possible (e.g. +, –, additional symbols such as ↑ and ↓ are available using the "Ω" tool in the editor). --> ==

Tony.Wang: Format change

2021-08-30T17:24:08Z

Format change

← Older revision		Revision as of 10:24, 30 August 2021
Line 8:		Line 8:
	\| considerations_intraoperative =		\| considerations_intraoperative =
	\| considerations_postoperative =		\| considerations_postoperative =
	}}		}}Electroconvulsive therapy (ECT) is a medically induced generalized seizure that consists of a 2 to 3 second latent phase is followed by a tonic (prolonged muscular contraction) phase lasting 10 to 12 seconds, then a clonic (repeated contraction) phase of 30 to 50 seconds.<ref name=":0">{{Cite book\|last=Murray, Michael J, Steven H. Rose, Denise J. Wedel, C T. Wass, Barry A. Harrison, and Jeff T. Mueller.\|first=\|title=Faust's Anesthesiology Review\|publisher=\|year=2015\|isbn=\|location=Print\|pages=Anesthesia for Electroconvulsive Therapy; 490-492}}</ref><ref name=":1">{{Cite book\|last=Pardo, Manuel, Ronald D Miller\|first=\|title=Basics of Anesthesia 7th Edition\|publisher=\|year=2017\|isbn=0323401155\|location=Print\|pages=669-671}}</ref> It is used for refractory depression (unipolar and bipolar types), depression with psychotic features, schizophrenia, and catatonia.<ref name=":1" /><ref name=":2">{{Cite web\|last=ACCRAC\|date=2019-03-13\|title=Episode 112: Anesthesia for ECT with Christina Miller\|url=http://accrac.com/episode-112-anesthesia-for-ect-with-christina-miller/\|access-date=2021-08-22\|website=ACCRAC Podcast\|language=en}}</ref>

	* <u>Background</u>:<ref name=":0">{{Cite book\|last=Murray, Michael J, Steven H. Rose, Denise J. Wedel, C T. Wass, Barry A. Harrison, and Jeff T. Mueller.\|first=\|title=Faust's Anesthesiology Review\|publisher=\|year=2015\|isbn=\|location=Print\|pages=Anesthesia for Electroconvulsive Therapy; 490-492}}</ref><ref name=":1">{{Cite book\|last=Pardo, Manuel, Ronald D Miller\|first=\|title=Basics of Anesthesia 7th Edition\|publisher=\|year=2017\|isbn=0323401155\|location=Print\|pages=669-671}}</ref>		ECT is monitored by EEG, with electrodes placed in left unilateral, right unilateral (most common, fewer memory side effects), and bifrontal. Goal seizure duration is 30-60 seconds. For seizures lasting longer than 120 seconds, termination can be achieved with midazolam/propofol. The initial session may require a dose titration to determine the appropriate electrical stimulus to evoke a seizure. Both the duration of individual seizure & cumulative seizure time between treatments correlated w/ clinical improvement of depression, with total number of ECT sessions determined by patient's clinical response. Repeated rounds of ECT have been shown to increase seizure threshold (try to decrease dose of methohexital or other induction agent if possible to limit size of electrical charge administered).
	** Seizures induced by ECT ~~are generalized seizures that consist of a 2 to 3 second latent phase~~ is ~~followed~~ by ~~a tonic~~ (~~prolonged muscular contraction~~) ~~phase lasting 10 to 12 seconds~~, ~~then a clonic (repeated contraction) phase of 30 to 50 seconds~~.
	** Seizure duration monitored by EEG; goal seizure duration 30-60 seconds. ~~If seizure > 120s consider~~ termination with midazolam/propofol.		Mortality risk is extremely low, at <1 in 75,000 treatments.<ref name=":0" /> Most common adverse events include transient arrhythmias (10%–40%), gastric aspiration (2.5%), and MSK disorders (0.4%) including fractures. Additional adverse events include pulmonary edema, headache, memory disturbance, and agitation. Very rarely Takotsubo cardiomyopathy, febrile reactions, or neurologic dysfunction may occur.
	** Initial session may require a dose titration to determine the appropriate electrical stimulus to evoke a seizure.
	** Configuration of electrode placement: Left unilateral, Right unilateral (most common, fewer memory side effects), & Bifrontal		Absolute contraindications include
	** Both the duration of individual seizure & cumulative seizure time between treatments correlated w/ clinical improvement of depression~~. Total #~~ of ~~treatments~~ determined by ~~Pt’s~~ clinical response.
	** Repeated rounds of ECT ↑ seizure threshold (try to decrease dose of methohexital or other induction agent if possible to limit size of electrical charge administered)
	*<u>Morbidity and Mortality ~~Rates~~<~~/u>:~~<ref name=":0" />
	** Mortality risk <1 in 75,000 treatments.
	** Most common adverse events~~: Transient~~ arrhythmias (10%–40%), gastric aspiration (2.5%), & MSK disorders (0.4%), including fractures.
	** Additional adverse events~~: Pulmonary~~ edema, HA, memory disturbance, & agitation. Very rarely ~~takotsubo~~ cardiomyopathy, febrile reactions, or neurologic dysfunction may occur.
	*<u>Indications</u>:<ref name=":1" /><ref name=":2">{{Cite web\|last=ACCRAC\|date=2019-03-13\|title=Episode 112: Anesthesia for ECT with Christina Miller\|url=http://accrac.com/episode-112-anesthesia-for-ect-with-christina-miller/\|access-date=2021-08-22\|website=ACCRAC Podcast\|language=en}}</ref>
	** Refractory Depression (unipolar and bipolar types), Depression with Psychotic features, Catatonia, and schizophrenia
	*<u>ABSOLUTE Contraindications</u>:<ref name=":0" /><ref name=":2" />		*<u>ABSOLUTE Contraindications</u>:<ref name=":0" /><ref name=":2" />
	** Untreated Pheochromocytoma		** Untreated Pheochromocytoma
Line 34:		Line 26:
	** Severe osteoporosis (fracture risk)		** Severe osteoporosis (fracture risk)
	** Thrombophlebitis		** Thrombophlebitis
	*<u>Physiologic Changes</u>:<ref name=":0" /><ref name=":2" />
	*<u>Pre-Induction Considerations: <ref name=":0" /><ref name=":1" /><ref name=":2" /></u>
	*<u>General Procedural Steps</u>: <ref name=":1" /><ref name=":2" />		*<u>General Procedural Steps</u>: <ref name=":1" /><ref name=":2" />
	*# Pre-oxygenate well prior to induction		*# Pre-oxygenate well prior to induction
Line 81:		Line 71:
	=== Operating room setup<!-- Describe any unique aspects of operating room preparation. Avoid excessively granular information. Use drug classes instead of specific drugs when appropriate. If none, this section may be removed. --> ===		=== Operating room setup<!-- Describe any unique aspects of operating room preparation. Avoid excessively granular information. Use drug classes instead of specific drugs when appropriate. If none, this section may be removed. --> ===

	=== Patient preparation and premedication<!-- Describe any unique considerations for patient preparation and premedication. If none, this section may be removed. --> ===		=== Patient preparation and premedication<!-- Describe any unique considerations for patient preparation and premedication. If none, this section may be removed. --><ref name=":0" /><ref name=":1" /><ref name=":2" /> ===

	* ''Psychiatric Medication Management'':		* ''Psychiatric Medication Management'':
Line 129:		Line 119:
	Supine or with HOB elevated		Supine or with HOB elevated

	=== Maintenance and surgical considerations<!-- Describe the important considerations and general approach to the maintenance of anesthesia, including potential complications. Be sure to include any steps to the surgical procedure that have anesthetic implications. --> ===		=== Maintenance and surgical considerations<!-- Describe the important considerations and general approach to the maintenance of anesthesia, including potential complications. Be sure to include any steps to the surgical procedure that have anesthetic implications. --><ref name=":0" /><ref name=":2" /> ===

	* ECT stimulus -> short initial parasympathetic response caused by vagal nerve stimulation followed by a large sympathetic discharge		* ECT stimulus -> short initial parasympathetic response caused by vagal nerve stimulation followed by a large sympathetic discharge
Line 190:		Line 180:
	\|		\|
	\|}		\|}
			== References ==
	<references />		<references />

	~~== References ==~~

	[[Category:Surgical procedures]]		[[Category:Surgical procedures]]

Tony.Wang: Formatting change

2021-08-30T17:02:43Z

Formatting change

Show changes

Ajaksic1 at 02:24, 22 August 2021

2021-08-22T02:24:34Z

Ajaksic1 at 02:19, 22 August 2021

2021-08-22T02:19:40Z

← Older revision		Revision as of 19:19, 21 August 2021
Line 26:		Line 26:
	#* ECT stimulus -> short initial parasympathetic response caused by vagal nerve stimulation followed by a large sympathetic discharge		#* ECT stimulus -> short initial parasympathetic response caused by vagal nerve stimulation followed by a large sympathetic discharge
	#* ''Cardiovascular''		#* ''Cardiovascular''
	#** 1st: Parasympathetic ~~discharge~~ may cause '''asystole''', bradycardia, PVCs, '''hypotension''', & ventricular escape rhythm.		#** 1st: Parasympathetic response may cause '''asystole''', bradycardia, PVCs, '''hypotension''', & ventricular escape rhythm.
	#*** ''If known profound parasympathetic response, can blunt ~~with a small dose of~~ glycopyrrolate pre-induciton''		#***''If known profound parasympathetic response, can blunt w/ glycopyrrolate pre-induciton''
	#** 2<sup>nd</sup>: Sympathetic tone ~~increases~~ with seizure generation		#** 2<sup>nd</sup>: Sympathetic tone ↑ with seizure generation -> ↑ HR, PVCs, bigeminy, trigeminy, sinus tachycardia, '''ST segment changes''' (↑ myocardial O2 consumption) & '''severe HTN'''.
	~~#*** Presents as increased~~ HR, PVCs, bigeminy, trigeminy, sinus tachycardia, '''ST segment changes''' (↑ myocardial O2 consumption) & '''severe HTN'''.		#*** Often resolves quickly, but if Pt requires intervention consider nitroglycerin, esmolol, or labetalol
	#*** Often resolves quickly, but if Pt requires intervention, ~~consider~~ esmolol or labetalol ~~for tachycardia or HTN~~		#* ''Respiratory'': Parasympathetic discharge -> at risk for laryngospasm, bronchoconstriction/wheezing
	#* ''Respiratory'':		#* ''Neuro:'' Initial constriction of cerebral vessels is followed by ↑ cerebral blood flow (1.5–7 times baseline) secondary to ↑ cerebral O2 consumption & ↑BP -> ↑ICP
	~~#** During initial parasympathetic~~ discharge at risk for laryngospasm, bronchoconstriction/wheezing		#* ''Neuroendocrine'': ↑ corticotropin, cortisol, & catecholamines.
	#* ''Neuro'':
	#** Initial constriction of cerebral vessels is followed by ↑ cerebral blood flow (1.5–7 times baseline) secondary to ↑ cerebral O2 consumption & ~~elevated BP~~ -> ~~↑ ICP~~
	#* ''Neuroendocrine'':
	#** ↑ corticotropin, cortisol, & catecholamines.
	#** Effects on glucose levels vary; consider Pre/Post glucose in insulin dependent patients.		#** Effects on glucose levels vary; consider Pre/Post glucose in insulin dependent patients.
	#* ''GI'': ↑ intragastric pressure		#* ''GI'': ↑ intragastric pressure

Ajaksic1 at 02:16, 22 August 2021

2021-08-22T02:16:07Z

← Older revision		Revision as of 19:16, 21 August 2021
Line 2:		Line 2:
	#* Seizures induced by ECT are generalized seizures that consist of a 2 to 3 second latent phase is followed by a tonic (prolonged muscular contraction) phase lasting 10 to 12 seconds, then a clonic (repeated contraction) phase of 30 to 50 seconds.		#* Seizures induced by ECT are generalized seizures that consist of a 2 to 3 second latent phase is followed by a tonic (prolonged muscular contraction) phase lasting 10 to 12 seconds, then a clonic (repeated contraction) phase of 30 to 50 seconds.
	#* Seizure duration monitored by EEG; goal seizure duration 30-60 seconds. If seizure > 120s consider termination with midazolam/propofol.		#* Seizure duration monitored by EEG; goal seizure duration 30-60 seconds. If seizure > 120s consider termination with midazolam/propofol.
	#* Initial session may require a dose titration to determine the appropriate electrical stimulus to evoke a seizure~~, which requires an appropriate duration of anesthesia & neuromuscular blockade~~.		#* Initial session may require a dose titration to determine the appropriate electrical stimulus to evoke a seizure.
	#* Configuration of electrode placement: Left unilateral, Right unilateral, ~~& Bifrontal~~		#* Configuration of electrode placement: Left unilateral, Right unilateral (most common, fewer memory side effects), & Bifrontal
	~~#** Right unilateral most commonly used to minimize~~ side effects ~~of ECT (ex; short- term cognitive dysfunction~~)		#* Both the duration of individual seizure & cumulative seizure time between treatments correlated w/ clinical improvement of depression. Total # of treatments determined by Pt’s clinical response.
	#* Both the duration of individual ~~Seizure~~ & cumulative seizure time between treatments correlated ~~with~~ clinical improvement of depression. ~~The total~~ # of treatments determined by Pt’s clinical response.
	#* Repeated rounds of ECT ↑ seizure threshold (try to decrease dose of methohexital or other induction agent if possible to limit size of electrical charge administered)		#* Repeated rounds of ECT ↑ seizure threshold (try to decrease dose of methohexital or other induction agent if possible to limit size of electrical charge administered)
	# <u>Morbidity and Mortality Rates</u>:<ref name=":0" />		# <u>Morbidity and Mortality Rates</u>:<ref name=":0" />
Line 25:		Line 24:
	#* Thrombophlebitis		#* Thrombophlebitis
	# <u>Physiologic Changes</u>:<ref name=":0" /><ref name=":2" />		# <u>Physiologic Changes</u>:<ref name=":0" /><ref name=":2" />
	#* ECT stimulus -> short initial parasympathetic response caused by vagal nerve stimulation followed by a large sympathetic discharge		#* ECT stimulus -> short initial parasympathetic response caused by vagal nerve stimulation followed by a large sympathetic discharge
	#* ''Cardiovascular''		#* ''Cardiovascular''
	#** 1st: Parasympathetic discharge may cause '''asystole''', bradycardia, PVCs, '''hypotension''', & ventricular escape rhythm.		#** 1st: Parasympathetic discharge may cause '''asystole''', bradycardia, PVCs, '''hypotension''', & ventricular escape rhythm.
Line 36:		Line 35:
	#* ''Neuro'':		#* ''Neuro'':
	#** Initial constriction of cerebral vessels is followed by ↑ cerebral blood flow (1.5–7 times baseline) secondary to ↑ cerebral O2 consumption & elevated BP -> ↑ ICP		#** Initial constriction of cerebral vessels is followed by ↑ cerebral blood flow (1.5–7 times baseline) secondary to ↑ cerebral O2 consumption & elevated BP -> ↑ ICP
	~~#** Preoxygenation prevent cerebral hypoxia.~~
	#* ''Neuroendocrine'':		#* ''Neuroendocrine'':
	#** ↑ corticotropin, cortisol, & catecholamines.		#** ↑ corticotropin, cortisol, & catecholamines.
Line 60:		Line 58:
	# <u>Access</u>: PIV x 1		# <u>Access</u>: PIV x 1
	# <u>Management of Induction & Seizure Sequelae</u>: <ref name=":0" /><ref name=":1" /><ref name=":2" />		# <u>Management of Induction & Seizure Sequelae</u>: <ref name=":0" /><ref name=":1" /><ref name=":2" />
	## '''Induction''':		##'''Induction''':
	##* Methohexital (Brevital) 0.5 to 1 mg/kg; least effect on Sz threshold		##* Methohexital (Brevital) 0.5 to 1 mg/kg; least effect on Sz threshold
	##* Etomidate: 0.2 to 0.3 mg/kg; maintains hemodynamic stability		##* Etomidate: 0.2 to 0.3 mg/kg; maintains hemodynamic stability
Line 73:		Line 71:
	### '''Glycopyrrolate''' 0.2mg to prevent bradycardia. Usually given prior to induction agents		### '''Glycopyrrolate''' 0.2mg to prevent bradycardia. Usually given prior to induction agents
	## '''Subsequent Sympathetic discharge''':		## '''Subsequent Sympathetic discharge''':
	### Nitroglycerin &/ot Beta blockers (esmolol, labetalol) can be used to attenuate sympathetic response.		### Nitroglycerin &/or Beta blockers (esmolol, labetalol) can be used to attenuate sympathetic response.
	### ''Hyperglycemia'' often seen in insulin dependent Pt -> BG Pre/Post		### ''Hyperglycemia'' often seen in insulin dependent Pt -> BG Pre/Post
	## '''Post-ECT delirium''' (or if flumazenil given Pre-Induction):		## '''Post-ECT delirium''' (or if flumazenil given Pre-Induction):

Ajaksic1 at 02:12, 22 August 2021

2021-08-22T02:12:19Z

← Older revision		Revision as of 19:12, 21 August 2021
Line 9:		Line 9:
	# <u>Morbidity and Mortality Rates</u>:<ref name=":0" />		# <u>Morbidity and Mortality Rates</u>:<ref name=":0" />
	#* Mortality risk <1 in 75,000 treatments.		#* Mortality risk <1 in 75,000 treatments.
	#* Most common adverse ~~outcomes~~:Transient arrhythmias (10%–40%), gastric aspiration (2.5%), & MSK disorders (0.4%), including fractures.		#* Most common adverse events: Transient arrhythmias (10%–40%), gastric aspiration (2.5%), & MSK disorders (0.4%), including fractures.
	#* Additional adverse events: Pulmonary edema, HA, memory disturbance, & agitation. Very rarely takotsubo cardiomyopathy, febrile reactions, or neurologic dysfunction may occur.		#* Additional adverse events: Pulmonary edema, HA, memory disturbance, & agitation. Very rarely takotsubo cardiomyopathy, febrile reactions, or neurologic dysfunction may occur.
	# <u>Indications</u>:<ref name=":1" /><ref name=":2">{{Cite web\|last=ACCRAC\|date=2019-03-13\|title=Episode 112: Anesthesia for ECT with Christina Miller\|url=http://accrac.com/episode-112-anesthesia-for-ect-with-christina-miller/\|access-date=2021-08-22\|website=ACCRAC Podcast\|language=en}}</ref>		# <u>Indications</u>:<ref name=":1" /><ref name=":2">{{Cite web\|last=ACCRAC\|date=2019-03-13\|title=Episode 112: Anesthesia for ECT with Christina Miller\|url=http://accrac.com/episode-112-anesthesia-for-ect-with-christina-miller/\|access-date=2021-08-22\|website=ACCRAC Podcast\|language=en}}</ref>

← Older revision		Revision as of 19:24, 21 August 2021
Line 57:		Line 57:
	##* Methohexital (Brevital) 0.5 to 1 mg/kg; least effect on Sz threshold		##* Methohexital (Brevital) 0.5 to 1 mg/kg; least effect on Sz threshold
	##* Etomidate: 0.2 to 0.3 mg/kg; maintains hemodynamic stability		##* Etomidate: 0.2 to 0.3 mg/kg; maintains hemodynamic stability
	##* Propofol: ↑ seizure threshold & ~~'''~~↓~~'''~~ seizure duration. Need higher stimulus voltages to achieve adequate seizure. ''May be useful in patients with history of long seizures''.		##* Propofol: ↑ seizure threshold & ↓ seizure duration. Need higher stimulus voltages to achieve adequate seizure. ''May be useful in patients with history of long seizures''.
	##* Ketamine: can cause post-ECT		##* Ketamine: can cause post-ECT confusion.
	##* Remifentanil 200-400 mcg as an adjunct to lower dose of methohexital needed; net '''↓''' Sz threshold. ~~Watch out~~ for chest wall rigidity ~~(difficult to mask) give succinylcholine asap if~~ unable to ventilate.		##* Remifentanil 200-400 mcg as an adjunct to lower dose of methohexital needed; net '''↓''' Sz threshold. Monitor for ↓HR/↓BP & chest wall rigidity. If unable to ventilate or very small TV, consider succinylcholine.
	##* Sevoflurane can be used for inhalational induction when no IV access possible.		##* Sevoflurane can be used for inhalational induction when no IV access possible.
	## '''Paralytic''':		## '''Paralytic''':
	### Succinylcholine 1- 1.5 mg/kg, titrate to adequate paralysis		### Succinylcholine 1- 1.5 mg/kg, titrate to adequate paralysis
	### Rocuronium - Low dose & only if patient has contraindication to succinylcholine (reverse with sugammadex)		### Rocuronium - Low dose & only if patient has contraindication to succinylcholine (reverse with sugammadex)
	## '''Initial PARAsympathetic discharge''':		## '''Initial PARAsympathetic discharge''':
	### ~~'''~~Glycopyrrolate~~'''~~ 0.2mg to prevent bradycardia. Usually given prior to induction agents		### Glycopyrrolate 0.2mg to prevent bradycardia. Usually given prior to induction agents
	## '''Subsequent Sympathetic discharge''':		## '''Subsequent Sympathetic discharge''':
	### Nitroglycerin &/or Beta blockers (esmolol, labetalol) can be used to attenuate sympathetic response.		### Nitroglycerin &/or Beta blockers (esmolol, labetalol) can be used to attenuate sympathetic response.
	### ''Hyperglycemia'' often seen in insulin dependent Pt -> BG Pre/Post		### ''Hyperglycemia'' often seen in insulin dependent Pt -> BG Pre/Post
	## '''Post-ECT ~~delirium~~''' (or if flumazenil given ~~Pre~~-~~Induction~~):		## '''Post-ECT Delirium''' (or if flumazenil given pre-induction):
	### Midazolam		### Midazolam 1-2mg
	# <u>General Procedural Steps</u>: <ref name=":1" /><ref name=":2" />		# <u>General Procedural Steps</u>: <ref name=":1" /><ref name=":2" />
	## ~~Preoxygenate~~ well prior to induction		## Pre-oxygenate well prior to induction
	## Once induction medications given & patient unconscious start mask ventilating & give paralytic		## Once induction medications given & patient unconscious start mask ventilating & give paralytic
	## Hyperventilate -> Hypocarbia (↓ seizure threshold)		## Hyperventilate -> Hypocarbia (↓ seizure threshold)
	## Bite guard placed prior to ECT initiation		## Bite guard placed prior to ECT initiation
	## After ECT & seizure completed remove bite guard and provide supportive airway management until patient regains consciousness.		## After ECT & seizure completed remove bite guard and provide supportive airway management until patient regains consciousness.

	#		#